Company: INSP
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001609550-25-000020
Chunk: 51

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 51
---
 (90.2)%Other income, net(5,644)(5,863)219 (3.7)%Income (loss) before income taxes4,159 (9,355)13,514 (144.5)%Income taxes1,167 650 517 79.5 %Net income (loss)$2,992 $(10,005)$12,997 (129.9)%

Revenue

Revenue increased $37.3 million, or 22.7%, to $201.3 million for the three months ended March 31, 2025 compared to $164.0 million for the three months ended March 31, 2024. These results reflect an increase in sales of our Inspire system of $37.8 million in the U.S. offset by a decrease of $0.5 million outside of the U.S. compared to the same prior year period. Overall revenue growth was primarily due to increased market penetration in existing centers, expansion into new territories and centers, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints.

Revenue information by region is summarized as follows:Three Months Ended March 31,20252024ChangeAmount% of RevenueAmount% of Revenue$%(in thousands, except percentages)United States$193,606 96.2 %$155,771 95.0 %$37,835 24.3 %All other countries7,711 3.8 %8,239 5.0 %(528)(6.4)%Total revenue$201,317 100.0 %$164,010 100.0 %$37,307 22.7 %

Revenue generated in the U.S. was $193.6 million for the three months ended March 31, 2025, an increase of $37.8 million, or 24.3%, compared to the three months ended March 31, 2024. Revenue growth in the U.S. was primarily due to increased market penetration in existing centers, the expansion into new territories and centers, and, we believe, increased physician and patient awareness of our Inspire system.

Revenue generated outside of the U.S. was $7.7 million in the three months ended March 31, 2025, a decrease of $0.5 million, or 6.4%, compared to the three months ended March 31,